Elite Pharmaceuticals, Inc. (ELTP)

Market Cap	385.28M -33.1%
Revenue (ttm)	148.87M +77.1%
Net Income	44.87M
EPS	0.03
Shares Out	1.08B
PE Ratio	11.92
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,196
Open	0.3600
Previous Close	0.3577
Day's Range	0.3503 - 0.3650
52-Week Range	0.3252 - 0.7400
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 17, 2026

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; P...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 65
• Stock Exchange: OTCMKTS
• Ticker Symbol: ELTP

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 7, 2026

Data Sources Report a data error